<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cardiovascular (CV) disease is the major cause of mortality and morbidity in individuals with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Individuals with <z:mp ids='MP_0002055'>diabetes</z:mp> often have a variety of factors such as <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:hpo ids='HP_0001513'>obesity</z:hpo>, which increase their risks of <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and CV disease </plain></SENT>
<SENT sid="2" pm="."><plain>The incretin hormones, such as glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1), induce the <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent secretion of insulin, improve beta-cell function and induce slowing of gastric emptying and feelings of satiety - which result in reduced food intake and <z:hpo ids='HP_0001824'>weight loss</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Therapeutic treatments targeting the incretin system, such as GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi>, offer the potential to address <z:hpo ids='HP_0006279'>beta-cell dysfunction</z:hpo> (one the underlying pathogenic mechanisms of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>), as well as the resulting <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Initial evidence now suggests that incretins could have beneficial effects on endothelial function and the CV system through both indirect effects on the reduction of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and direct effects mediated through GLP-1 receptor-dependent and -independent mechanisms </plain></SENT>
<SENT sid="5" pm="."><plain>If these initial findings are confirmed in larger clinical trials, GLP-1 receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> could help to address the major CV risks faced by patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>